50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Sell every Stock except ONE (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
Sell every Stock except ONE (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
Sell every Stock except ONE (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce & Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Sell every Stock except ONE (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
Sell every Stock except ONE (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
Sell every Stock except ONE (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce & Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Sell every Stock except ONE (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
Sell every Stock except ONE (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
Sell every Stock except ONE (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce & Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Sell every Stock except ONE (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
Sell every Stock except ONE (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
Sell every Stock except ONE (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce & Gabbana archives for Milan show
NASDAQ:SRPT

Sarepta Therapeutics - SRPT Stock Forecast, Price & News

$108.19
-2.68 (-2.42%)
(As of 09/23/2022 12:00 AM ET)
Add
Compare
Today's Range
$104.68
$109.70
50-Day Range
$82.54
$119.24
52-Week Range
$61.28
$120.23
Volume
846,360 shs
Average Volume
1.17 million shs
Market Capitalization
$9.47 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$131.31

Sarepta Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
21.4% Upside
$131.31 Price Target
Short Interest
Bearish
7.48% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.65
Upright™ Environmental Score
News Sentiment
0.00mentions of Sarepta Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$10.96 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($6.89) to ($4.86) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.80 out of 5 stars

Medical Sector

833rd out of 1,080 stocks

Pharmaceutical Preparations Industry

393rd out of 535 stocks

SRPT stock logo

About Sarepta Therapeutics (NASDAQ:SRPT) Stock

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Receive SRPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SRPT Stock News Headlines

SRPT Sarepta Therapeutics, Inc.
Sarepta prices almost $1 billion convertible bond offering
Sarepta (SRPT) Stock Up 76.8% in Three Months: Here's Why
5SRPT : Sarepta Therapeutics Whale Trades Spotted
Did Sarepta Therapeutics Just Unveil a Breakthrough?
See More Headlines
Receive SRPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SRPT Company Calendar

Last Earnings
11/03/2021
Today
9/24/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SRPT
Previous Symbol
NASDAQ:AVII
Employees
840
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$131.31
High Stock Price Forecast
$182.00
Low Stock Price Forecast
$90.00
Forecasted Upside/Downside
+21.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
12 Analysts

Profitability

Net Income
$-418,780,000.00
Pretax Margin
-60.11%

Debt

Sales & Book Value

Annual Sales
$701.89 million
Book Value
$10.66 per share

Miscellaneous

Free Float
81,964,000
Market Cap
$9.47 billion
Optionable
Optionable
Beta
1.20

Key Executives

  • Mr. Douglas S. Ingram Esq.Mr. Douglas S. Ingram Esq. (Age 59)
    Pres, CEO & Director
    Comp: $1.55M
  • Mr. Ian Michael Estepan (Age 46)
    Exec. VP & CFO
    Comp: $861.75k
  • Mr. William F. Ciambrone (Age 58)
    Exec. VP of Technical Operations
    Comp: $780.28k
  • Dr. Louise R. Rodino-Klapac Ph.D.Dr. Louise R. Rodino-Klapac Ph.D. (Age 44)
    Exec. VP, Chief Scientific Officer and Head of R&D
    Comp: $929.68k
  • Mr. Ryan E. Brown (Age 44)
    Sr. VP, Gen. Counsel & Corp. Sec.
    Comp: $913.64k
  • Mary Jenkins
    Sr. Mang. of Investor Relations
  • Ms. Alison Nasisi
    Chief People Officer & VP
  • Dr. Diane L. Berry
    Sr. VP of Global Health Policy and Gov. & Patient Affairs
  • Mr. Dallan Murray
    Sr. VP & Chief Customer Officer
  • Mr. Joseph Bratica (Age 58)
    Controller & VP













SRPT Stock - Frequently Asked Questions

Should I buy or sell Sarepta Therapeutics stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SRPT shares.
View SRPT analyst ratings
or view top-rated stocks.

What is Sarepta Therapeutics' stock price forecast for 2022?

12 analysts have issued 1-year target prices for Sarepta Therapeutics' stock. Their SRPT share price forecasts range from $90.00 to $182.00. On average, they anticipate the company's share price to reach $131.31 in the next twelve months. This suggests a possible upside of 21.4% from the stock's current price.
View analysts price targets for SRPT
or view top-rated stocks among Wall Street analysts.

How have SRPT shares performed in 2022?

Sarepta Therapeutics' stock was trading at $90.05 on January 1st, 2022. Since then, SRPT shares have increased by 20.1% and is now trading at $108.19.
View the best growth stocks for 2022 here
.

When is Sarepta Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our SRPT earnings forecast
.

How were Sarepta Therapeutics' earnings last quarter?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) released its quarterly earnings data on Wednesday, November, 3rd. The biotechnology company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.86) by $1.26. The biotechnology company earned $189.41 million during the quarter, compared to the consensus estimate of $170.13 million. Sarepta Therapeutics had a negative trailing twelve-month return on equity of 67.98% and a negative net margin of 60.66%. During the same period last year, the firm posted ($2.50) EPS.

What guidance has Sarepta Therapeutics issued on next quarter's earnings?

Sarepta Therapeutics updated its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $905.00 million-$920.00 million, compared to the consensus revenue estimate of $899.91 million.

What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO?

15 employees have rated Sarepta Therapeutics Chief Executive Officer Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among the company's employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Sarepta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and Walt Disney (DIS).

What is Sarepta Therapeutics' stock symbol?

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."

Who are Sarepta Therapeutics' major shareholders?

Sarepta Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Sands Capital Management LLC (4.24%), Price T Rowe Associates Inc. MD (1.33%), Federated Hermes Inc. (0.80%), Casdin Capital LLC (0.74%), Frontier Capital Management Co. LLC (0.51%) and Assenagon Asset Management S.A. (0.51%). Insiders that own company stock include Alexander Cumbo, David T Howton, Douglas S Ingram, Hans Lennart Rudolf Wigzell, Joseph Bratica, Louise Rodino-Klapac, M Kathleen Behrens, Michael Andrew Chambers, Richard Barry and Sandesh Mahatme.
View institutional ownership trends
.

How do I buy shares of Sarepta Therapeutics?

Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sarepta Therapeutics' stock price today?

One share of SRPT stock can currently be purchased for approximately $108.19.

How much money does Sarepta Therapeutics make?

Sarepta Therapeutics (NASDAQ:SRPT) has a market capitalization of $9.47 billion and generates $701.89 million in revenue each year. The biotechnology company earns $-418,780,000.00 in net income (profit) each year or ($5.87) on an earnings per share basis.

How many employees does Sarepta Therapeutics have?

The company employs 840 workers across the globe.

How can I contact Sarepta Therapeutics?

Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The official website for the company is www.sareptatherapeutics.com. The biotechnology company can be reached via phone at (857) 242-4000, via email at investors@sarepta.com, or via fax at 425-354-5038.

This page (NASDAQ:SRPT) was last updated on 9/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.